The mystery of diabetes and atherosclerosis: Time for a new plot

Diabetes

Volumn 46, Issue 3, 1997, Pages 327-334

  Semenkovich, Clay F ^a   Heinecke, Jay W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID SYNTHASE; LIPOPROTEIN LIPASE;

ATHEROGENESIS; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPID OXIDATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 0031047740     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.3.327     Document Type: Review

References (121)

1. Stamler J, Wentworth D, Neaton JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823-2828, 1986
2. Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 97:1767-1773, 1996
3. Pyorala K, Pedersen TR, Kjekshus J, the Scandinavian Simvastatin Survival Study (4S): The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease (Abstract). Diabetes 44 (Suppl. 1):35A, 1995
4. Bierman EL: George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 12:647-656, 1992
5. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM: Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care 15:1156-1167, 1992
6. Ginsberg HN: Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14:839-855, 1991
7. Colwell JA, Lopes-Virella MF: A review of the development of large-vessel disease in diabetes mellitus. Am J Med 85:113-118, 1988
8. Semenkovich CF, Chen S-H, Wims M, Luo C-C, Li W-H, Chan L: Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation and evolution. J Lipid Res 30:423-431, 1989
9. Seip RL, Angelopoulos TJ, Semenkovich CF: Exercise induces human lipoprotein lipase gene expression in skeletal muscle but not adipose tissue. Am J Physiol 268:E229-E236, 1995
10. Tsutsumi K, Inoue Y, Shima A, Murase T: Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44:414-417, 1995
11. Shimada M, Ishibashi S, Gotoda T, Kawamura M, Yamamoto K, Inaba T, Harada K, Ohsuga J, Perrey S, Yazaki Y, Yamada N: Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:1688-1694, 1995
12. Wilson DE, Hata A, Kwong LK, Lingam A, Shuhua J, Ridinger D, Yeager C, Kaltenborn KC, Iverius PH, Lalouel JM: Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and noninsulin-dependent diabetes. J Clin Invest 92:203-211, 1993
13. Fredrickson DS, Lees RS: Familial hyperlipoproteinemia. In The Metabolic Basis of Inherited Disease. 2nd ed. Stanbury JB, Wyngaarden JB, Fredrickson DS, Eds. New York, McGraw-Hill, 1965, p. 429-485
14. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M: Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335:848-854, 1996
15. Yang W-S, Nevin DN, Peng R, Brunzell JD, Deeb SS: A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci USA 92:4462-4466, 1995 (Correction, 93:524, 1996)
16. Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, Beisiegel U, Feussner G, Miller G, Humphries SE, Talmud PJ: Interaction of the lipoprotein lipase asparagine 291-serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. J Lipid Res 36:2104-2112, 1995
17. Reymer PWA, Gagne E, Groenemeyer BE, Zhang H, Forsyth I, Jansen H, Seidell JC, Kromhout D, Lie KE, Kastelein J, Hayden MR: A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genet 10:28-34, 1995
18. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 14:1767-1774, 1994
19. Miesenbock G, Holzl B, Foger B, Brandstatter E, Paulweber B, Sandhofer F, Patsch JR: Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 91:448-455, 1993
20. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T: The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92:411-417, 1993
21. O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A: Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest 89:1544-1550, 1992
22. Renier G, Skamene E, DeSanctis JB, Radzioch D: High macrophage lipoprotein lipase expression and secretion are associated in inbred murine strains with susceptibility to atherosclerosis. Arterioscler Thromb 13:190-196, 1992
23. Saxena U, Klein MG, Vanni TM, Goldberg IJ: Lipoprotein lipase increases low density lipoprotein retention by subendothelial matrix. J Clin Invest 89:373-380, 1992
24. Sivaram P, Choi SY, Curtiss LK, Goldberg IJ: An amino-terminal fragment of apolipoprotein B binds to lipoprotein lipase and may facilitate its binding to endothelial cells. J Biol Chem 269:9409-9412, 1994
25. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551-561, 1995
26. Coleman T, Seip RL, Gimble JM, Lee D, Maeda N, Semenkovich CF: COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem 270:12518-12525, 1995
27. Coleman T, Seip RL, Maeda N, Semenkovich CF: Targeted inactivation of murine lipoprotein lipase (Abstract). Diabetes (Suppl. 1) 44A, 1995
28. Pollare T, Vessby B, Lithell H: Lipoprotein lipase in skeletal muscle is related to insulin sensitivity. Arterioscl Thromb 11:1192-1203, 1991
29. Ginsberg HN: Synthesis and secretion of apolipoprotein B from cultured liver cells. Curr Opin Lipidol 6:275-280, 1995
30. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-471, 1992
31. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353, 1992
32. Yamamoto K, Shimano H, Shimada M, Kawamura M, Gotoda T, Harada K, Ohsuga J, Yazaki Y, Yamada N: Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Diabetes 44:580-585, 1995
33. Laakso M, Kesaniemi A, Kervinen K, Jauhiainen M, Pyorala K: Relation of coronary heart disease and apolipoprotein phenotype in patients with non-insulin dependent diabetes. Br Med J 303:1159-1162, 1991
34. Eichner JE, Ferrell RE, Kamboh MI, Kuller LH, Becker DJ, Drash AL, Stein EA, Orchard TJ: The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study IX. Metabolism 41:347-351, 1992
35. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S: Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 45:63-71, 1996
36. Bergeron N, Havel RJ: Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε4 allele. J Clin Invest 97:65-72, 1996
37. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y, Yamada N: Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 95:469-476, 1995
38. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE: Macrophage-speciflc expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96:2170-2179, 1995
39. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL: Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249:790-793, 1990
40. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL: Mechanisms of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90:1889-1900, 1992
41. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96:2071-2074, 1995
42. Schonfeld G, George PK, Miller J, Reilly P, Witztum J: Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28:1001-1010, 1979
43. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL: An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 90:4562-4566, 1993
44. Chen M, Breslow JL, Li W, Leff T: Transcriptional regulation of the apo C-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 35:1918-1924, 1994
45. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T: Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96:2601-2605, 1995
46. Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274, 1993
47. Ritter MC, Bagdade JD: Contribution of glycaemic control, endogenous lipoproteins and cholesteryl ester transfer protein to accelerated cholesteryl ester transfer in IDDM. Eur J Clin Invest 24:607-614, 1994
48. Kahri J, Syvanne M, Taskinen M-R: Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism 43:1498-1502, 1994
49. Marotti KR, Castle CK, Boyle YP, Lin AH, Murray RW, Melchior GW: Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364:73-75, 1993
50. Gianturco SH, Brown FB, Gotto AM, Bradley WA: Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal skin fibroblasts. J Lipid Res 23:984-993, 1982
51. Fielding PE, Ishikawa Y, Fielding CJ: Apolipoprotein E mediates the binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding. J Biol Chem 264:12462-12466, 1989
52. Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesaniemi YA: DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro- and microangiopathy in non-insulin-dependent diabetes mellitus. Clin Genetics 46:217-227, 1994
53. Hillgartner FB, Salati LM, Goodridge AG: Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol Rev 75:47-76, 1995
54. Semenkovich CF, Coleman T, Fiedorek FT Jr: Human fatty acid synthase mRNA: tissue distribution, genetic mapping, and kinetics of decay after glucose deprivation. J Lipid Res 36:1507-1521, 1995
55. Groop LC, Bonadonna RC, DelPrato S, Ratheiser, Zyck K, Ferrannini E, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
56. Schwarz J-M, Neese RA, Turner S, Dare D, Hellerstein MK: Short-term alterations in carbohydrate energy intake in humans: striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest 96:2735-2743, 1995
57. Prip-Buus C, Perdereau D, Foufelle F, Maury J, Ferre P, Girard J: Induction of fatty acid synthase gene expression by glucose in primary culture of rat hepatocytes: dependency upon glucokinase activity. Eur J Biochem 230:309-315, 1995
58. Clarke SD, Armstrong MK, Jump DB: Dietary polyunsaturated fats uniquely suppress rat liver fatty acid synthase and S14 mRNA content. J Nutr 120:225-231, 1990
59. Dudek SM, Semenkovich CF: Essential amino acids regulate fatty acid synthase expression through an uncharged transfer RNA-dependent mechanism. J Biol Chem 270:29323-29329, 1995
60. Pijl H, Potter van Loon BJ, Toornvliet AC, Radder JK, Onkenhout W, Frolich M, Meinders AE: Insulin-induced decline of plasma amino acid concentrations in obese subjects with and without non-insulin-dependent diabetes. Metabolism 43:640-646, 1994
61. Semenkovich CF, Coleman T, Goforth R: Physiologic concentrations of glucose regulate fatty acid synthase activity in HepG2 cells by mediating fatty acid synthase mRNA stability. J Biol Chem 268:6961-6970, 1993
62. Bennett MK, Lopez JM, Sanchez HB, Osborne TF: Sterol regulation of fatty acid synthase promoter: coordinate feedback regulation of two major lipid pathways. J Biol Chem 270:25578-25583, 1995
63. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47, 1986
64. Berliner JA, Heinecke JW: The role of oxidized lipoprotein in atherogenesis. Free Rad Biol Med 20:707-727, 1996
65. Baynes JW: Perspectives in diabetes: role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
66. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL: Glycosylation of LDL enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37:550-557, 1988
67. Schleicher E, Olgemoller B, Schon J, Durst J, Wieland OH: Limited nonenzymatic glycosylation of low density lipoprotein does not alter its catabolism in tissue culture. Biochim Biophys Acta 846:226-233, 1985
68. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261, 1983
69. Haberland ME, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241:215-218, 1988
70. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butter S, Witztum JL: Distribution of oxidation specific lipid-protein adducte and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 10:336-349, 1990
71. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G: Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 8:768-777, 1988
72. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989
73. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells. J Clin Invest 74:1890-1894, 1984
74. Steinbrecher V, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of phospholipids. Proc Natl Acad Sci USA 81:3883-3887, 1984
75. Morel DW, DiCorleto PE, Chisolm GM: Endothelial and smooth muscle cells alter LDL in vitro by free radical oxidation. Arteriosclerosis 4:357-364, 1984
76. Morel DW, Chisolm GM: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 30:1827-1834, 1989
77. Hunt JV, Smith CC, Wolf SP: Oxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39:1420-1424, 1990
78. Kawamura M, Heinecke JW, Chait A: Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94:771-778, 1994
79. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438, 1993
80. Bacula R, Makita Z, Vega G, Grundy SM, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 263:2893-2898, 1994
81. Bunn HF, Higgins PJ: Reactions of monosaccharides with proteins: possible evolutionary significance. Science 213:222-224, 1981
82. Monnier VM, Cerami A: Nonenzymatic browning in vivo: possible processes for aging of long-lived proteins. Science 211:491-493, 1981
83. Ledl F, Schleicher E: New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl 29:565-594, 1990
84. Brownlee M: Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med 42:159-166, 1991
85. Bucala R, Cerami A: Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharm 23:1-4, 1992
86. ε-(carboxymethyl)lysine as a degradation product of fructoselysine in glycated proteins. J Biol Chem 261:4889-4894, 1986
87. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J Biol Chem 264:21597-21602, 1989
88. Baynes JW: Role of metal-catalyzed autoxidation in Maillard reaction damage to proteins in vivo. Redox Reports 1:31-35, 1995
89. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
90. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycosylation: glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes and ageing. Biochem J 256:205-212, 1988
91. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad Biol Med 10:339-352, 1991
92. Klebanoff SJ: Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93:480-489, 1980
93. Daugherty A, Rateri DL, Dunn JL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444, 1994
94. Heinecke JW, Li W, Daehnke HL, Goldstein J: Dityrosine, a specific marker of oxidation, is produced by the myeloperoxidase-hydrogen peroxide chloride system of human neutrophils and macrophages. J Biol Chem 268:4069-4077, 1993
95. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97:1535-1544, 1996
96. King GL, Shiba T, Oliver J, Inogvchi T, Bursell SE: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 45:179-188, 1994
97. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Fener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
98. Jacob JS, Cistola D, Hsu FF, Muzaffar S, Mueller DM, Hazen SL, Heinecke JW: Human phagocytes employ myeloperoxidase to synthesize dityrosine, trityrosine, pulcherosine and isodityrosine by a tyrosyl radical-dependent mechanism. J Biol Chem 271:19950-19956, 1996
99. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW: Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 98:1283-1289, 1996
100. Li Y, Ferrante A, Poulos A, Harvey DP: Neutrophil oxygen radical generation: synergistic responses to tumor necrosis factor and mono/polyunsaturated fatty acids. J Clin Invest 97:1605-1609, 1996
101. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharm Rev 43:109-142, 1991
102. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and Superoxide. Proc Natl Acad Sci USA 87:1620-1624, 1990
103. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S: Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 330:181-185, 1993
104. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, White CR: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe-Seyler 375:81-88, 1994
105. Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R: The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1180:73-82, 1992
106. Yates MJ, Lambert LE, Whitten JP, MacDonald I, Mano M, Ku G, Mao SJT: A protective role for nitric oxide in the oxidative modification of low density lipoprotein by mouse macrophages. FEBS Lett 309:135-138, 1992
107. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S: Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett 334:170-174, 1993
108. Cooke JP, Tsao PS: Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 14:653-655, 1994
109. Patel V, Rassman S, Newsom R, Wiek J, Kohner E: Retinal blood flow in diabetic retinopathy. Br Med J 305:678-683, 1992
110. Traub O, Van Bibber R: Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. West J Med 162:439-445, 1995
111. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide. J Clin Invest 87:432-438, 1991
112. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
113. Corbett JA, Tilton RG, Chang K, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
114. Sparrow CP, Parthasarathy S, Steinberg D: Enzymatic modification of LDL by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res 29:745-753, 1988
115. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioia T, Witztum JL, Steinberg D: Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 87:6959-6963, 1987
116. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK: Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 96:504-510, 1995
117. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22-28, 1996
118. Stephens NG, Parsons A, Schonfeld PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). Lancet 347:781-786, 1996
119. Tsai EC, Hirsch IB, Brunzell JB, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010-1014, 1994
120. Tribble DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93:189-199, 1992
121. Chait A, Brazg RL, Tribble DL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94:350-356, 1993